Logo

Janssen Receives EC's Approval for Expanded Use of Erleada (apalutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer

Share this

Janssen Receives EC's Approval for Expanded Use of Erleada (apalutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer

Shots:

  • The EC’s approval is based on P-III TITAN study assessing Erleada + ADT vs PBO + ADT in 1052 patients in a ratio (1:1) with mHSPC regardless of the extent of disease or prior docetaxel treatment history across 23 countries
  • The P-III TITAN study results: improvement in OS with a 33% reduction in risk of death; 52% reduction in rPFS; OS rates after a median follow up of 22.7mos. (82% vs 74%)
  • Erleada is an androgen receptor inhibitor- indicated to treat patients with nmCRPC who are at high risk of developing mHSPC in the EU

Click here ­to­ read full press release/ article 

Ref: Janssen | Image: Janssen


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions